Fundamentals · ZTS
Valuation Summary for ZTS
AI-generated plain-English read of valuation summary for ZTS. Updated daily.
Rich multiples, compressing
moderateMultiples (18.9x) are rich but compressing — the premium is beginning to unwind. Watch whether compression stabilises at fair territory or overshoots into cheap.
What will probably happen
- Multiple compression is ongoing — expect continued price pressure unless earnings revisions reverse the trend.
- Modest income yield provides a partial floor while waiting for valuation normalisation.
What to do
- If you HOLD this stock
- Valuation doesn't give a strong signal for or against adding. Hold and monitor earnings delivery against the current multiple.
- If you're EVALUATING this stock
- Expensive entry. If you must own it, wait for a 10–15% multiple compression or a significant earnings beat that 'grows into' the valuation.
- If you trade OPTIONS
- Sell covered calls to reduce effective cost basis while waiting for multiple normalisation. Long puts make sense if you expect a near-term earnings miss to catalyse compression.
9 quarters / 3 populated multiples — directionally informative; use more data for full conviction.
Technical details
Technical analysis
- P/Book
- 15.4x
- P/Sales
- 5.3x
- EV/EBITDA
- —
- FCF yield
- —
- EV/Revenue
- —
- P/E (forward)
- —
- Dividend yield
- 1.8%
- Earnings yield
- —
- Income profile
- Balanced Income
- P/E (trailing)
- 18.9x
- Sector context
- Pharmaceuticals
- Sector comparison
- Unknown Vs Sector
- Absolute valuation
- Richly Valued
- History (quarters)
- 9
- Multiple trajectory
- Compressing
Key levels
| Level | Value |
|---|---|
| pb ratio | 15.444 |
| pe ratio | 18.892 |
| ps ratio | 5.251 |
| n quarters | 9 |
| prior year pe | 29.178 |
| dividend yield | 0.018 |
Caveats
- Multiples should be read alongside growth and quality metrics — a low P/E on declining earnings isn't cheap, it's a value trap warning.
- Sector context wasn't provided — absolute multiples may mislead without industry comparison.